



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006, 235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

CIN No. L85110KA1987PLC008739

SML/23/2016-17

Dated 30th May, 2016

To
Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

To
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Outcome of Board Meeting - Reg.
Ref: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements)
Regulations, 2015; Scrip Code: 530549; SHILPAMED**


With reference to the captioned subject, Please find the attached documents in terms of regulation 33 of SEBI (LODR) Regulations, 2015:

1. Annual Audited Standalone and consolidated Financial Results for the quarter and financial year ended 31st March, 2016.
2. Standalone and Consolidated Statement of Assets and Liabilities for the half year ended 31st March, 2016.
3. Auditor's Report on quarterly Financial Results and year to date Standalone and Consolidated Financials of the Company.

It is further intimated that meeting was commenced at 11.00 A.M. and ended at 1.40 P.M.

This is for your information and necessary records.

Yours faithfully,
For **SHILPA MEDICARE LIMITED**


OMPRAKASH INNANI
CHAIRMAN
DIN No:01301385



Encl:a.a



SHILPA MEDICARE LIMITED

CIN:L85110KA1987PLC008739

Regd. Office: "Shilpa House", 12-6-214/A1, Hyderabad Road, Raichur-584135(Karnataka)

STATEMENT OF STANDALONE AND CONSOLIDATED AUDITED RESULTS FOR THE FOURTH QUARTER AND FOR THE YEAR ENDED 31ST MARCH-2016
(Rs in Lacs)

	Particulars	Quarter Ended						Year Ended			
		Standalone			Consolidated			Standalone		Consolidated	
		31.03.16	31.12.15	31.03.15	31.03.16	31.12.15	31.03.15	31.03.16	31.03.15	31.03.16	31.03.15
		Audited	Unaudited	Audited	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Income from operations										
	(a) Net sales/income from operations (Net of Excise Duty)	17955.31	18895.91	15010.32	19848.36	19824.03	16673.27	67579.06	56540.21	71936.62	61379.91
	Total income from operations (net)	17955.31	18895.91	15010.32	19848.36	19824.03	16673.27	67579.06	56540.21	71936.62	61379.91
2	Expenses										
	(a) Cost of materials consumed	8494.79	9530.05	6525.07	9010.83	9681.02	6817.47	36046.75	30786.61	37041.98	31902.43
	(b) Purchases of stock-in-trade	67.68	242.19	209.81	67.68	242.19	209.81	381.00	864.17	381.00	864.17
	(c) Changes in inventories of finished goods, WIP, Stock in Trade	332.77	929.05	656.83	-6.02	993.35	967.51	(254.74)	(568.49)	(679.88)	(296.71)
	(d) Employee benefits expense	1708.19	1878.28	1869.78	2368.72	2522.26	2479.40	6697.47	5648.85	9144.73	8230.11
	(e) Depreciation and amortisation expense	541.85	550.06	483.49	838.03	844.54	540.61	2119.03	1908.50	2862.91	2141.17
	(f) Other expenses	2491.48	1996.67	1896.94	3418.54	2496.50	2421.74	8220.49	6156.29	10513.48	7816.38
	Total Expense	13636.75	15126.31	11641.92	15697.79	16779.87	13436.54	53210.00	44795.93	59264.22	50657.55
3	Profit/(Loss) from Operations before Other Income, Finance Costs & exceptional items (1-2)	4318.55	3769.61	3368.40	4150.56	3044.16	3236.73	14369.06	11744.28	12672.41	10722.37
4	Other Income	160.34	225.07	109.40	105.05	251.16	80.33	680.52	545.34	464.21	479.89
5	Profit/(Loss) from Ordinary activities before finance cost & exceptional items (3+/-4)	4478.89	3994.68	3477.80	4255.61	3295.32	3317.06	15049.58	12289.62	13136.62	11202.25
6	Finance costs	70.72	82.62	91.61	221.46	233.00	95.45	327.19	387.98	686.48	405.02
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5 +/- 6)	4408.17	3912.05	3386.19	4034.15	3062.32	3221.61	14722.40	11901.64	12450.13	10797.23
8	Exceptional items*	0.00	0.00	0.00	0.00	0.00	0.00	241.96	0.00	241.96	-4.83
9	Profit/(Loss) from Ordinary Activities before tax (7 +/- 8)	4408.17	3912.05	3386.19	4034.15	3062.32	3221.61	14480.44	11901.64	12208.18	10792.40
10	Tax expense	1130.25	699.93	1031.96	230.92	574.82	1026.58	3449.61	3483.53	2338.76	3521.58
11	Net Profit/(Loss) from ordinary activities after tax (9 +/-10)	3277.92	3212.12	2354.23	3803.22	2487.50	2195.03	11030.83	8418.11	9869.42	7270.82
12	Extraordinary Items Income / (Expenses)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
13	Net Profit/(Loss) for the period (11+12)	3277.92	3212.12	2354.23	3803.22	2487.50	2195.03	11030.83	8418.11	9869.42	7270.82
14	Share of Profit / (Loss) of associates	-	-	-	-	0.00	0.00	-	-	0.00	-
15	Add/(Gain)/ loss pertaining to Minority Interest	-	-	-	55.94	313.27	52.38	-	-	506.83	106.65
16	Net Profit / (loss) after taxes, minority interest and share of profit/(loss) of associates (13+/-14+/-15)	3277.92	3212.12	2354.23	3747.29	2800.77	2247.41	11030.83	8418.11	10376.25	7377.47
17	Paid-up equity share capital (Face value of Rs 1/-)(Refer Note No:10)	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	66391.43	55538.56	63919.28	53923.10
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs. 1/-each) (not annualized);(Refer Note No:10)										
	a) Basic	4.25	4.17	3.05	4.86	3.63	2.91	14.31	10.97	13.46	9.62
	b) Diluted	4.25	4.17	3.05	4.86	3.63	2.91	14.31	10.97	13.46	9.62
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs. 1/- each) (not annualized); (Refer Note No:10)										
	a) Basic	4.25	4.17	3.05	4.86	3.63	2.91	14.31	10.97	13.46	9.61
	b) Diluted	4.25	4.17	3.05	4.86	3.63	2.91	14.31	10.97	13.46	9.61



Notes:

- 1 The Audited Financial Results have been reviewed by the Audit Committee and approved at the Board Meeting.
- 2 Exceptional items represents Loss on buy back of shares during the year by Makindus Inc(Subsidiary). As a result of such buy back the share holding of Shilpa Medicare Ltd in Makindus Inc(Subsidiary) has come down from 70% to 55.78%.
- 3 Q4 - Consolidated Results include sales figure of Rs.39.92 lakhs (Nil) and net loss of Rs.361.94 Lakhs (Profit of Rs.3.66 lakhs) respectively of Raichem Medicare Pvt Ltd (subsidiary Co) which has started its operations on 25.08.2015
- 4 Consolidated Results for the year include sales figure of Rs 65.81 Lakhs (Rs. Nil) and net loss of Rs 713.15 Lakhs (Profit of Rs 83.37 Lakhs) respectively of Raichem Medicare Pvt Ltd (subsidiary Co) which has started its operations on 25.08.2015.
- 5 Q4 - Consolidated Results include a figure of Rs 200.79 lakhs (Rs. NIL) sales and net loss of Rs 86.84 Lakhs(Loss of Rs 294.30 Lakhs) in respect of Maia, Makindus and INM Technologies Pvt Ltd taken together which are subsidiaries/ JV Co's of Shilpa Medicare Ltd and which are in the investment phase of their R&D activities and are yet to start generating operational revenues.
- 6 Consolidated Results include a figure of Rs 289.76 Lakhs (Rs.NIL) sales and net loss of Rs 532.52 Lakhs (Net Loss of Rs 693.17 Lakhs) in respect of Maia, Makindus and INM Technologies Pvt Ltd taken together which are subsidiaries/ JV Co's of Shilpa Medicare Ltd and which are in the investment phase of their R&D activities and are yet to start generating operational revenues.
- 7 Koanaa Healthcare Limited has become wholly owned subsidiary of Shilpa Medicare Limited w.e.f 02.11.2015
- 8 Reva Medicare Pvt Ltd is a Joint Venture entity w.e.f 12.02.2016 The Company owns 50.001% of paid up Equity Capital
- 9 As per AS-17 reporting segment is only one i.e. Bulk Drug & API. Therefore segment reporting is not applicable.
- 10 Product Registration Fees of Rs.118.78 lakhs (Nil) paid by Koanaa Healthcare Limited, UK (wholly Owned Subsidiary) has been charged to P&L A/c vis-à-vis the Holding Co accounting policy of capitalizing the same as Intangible Asset. This has resulted in decrease in consolidated Net Profit of the Company by said amount.
- 11 Tax Expenses includes Current and Deferred Tax.
- 12 The face value of Equity Share of the Company has been reduced from Rs.2/- per share to Rs. 1/- on sub-division of shares as approved by the shareholders in the AGM held on 28th Sep,2015.Hence, EPS for all periods presented has been calculated considering the face value of Re. 1/- per share.
- 13 Figures of the previous year/quarter have been regrouped/rearranged wherever necessary.

* Figures in brackets represents amount for period and Quarter ended as at 31.03.2015.

Place:Hyderabad
Date: 30.05.2016

By the order of the Board of Directors
for SHILPA MEDICARE LIMITED


Chairman



**SHILPA MEDICARE LIMITED**

CIN:L85110KA1987PLC008739

Regd.Office: " Shilpa House", 12-6-214/A1 , Hyderabad Road, Raichur-584135(Karnataka)

STANDALONE/CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH-2016
(Rs. in Lacs)

Particulars	Standalone		Consolidated	
	31.03.2016	31.03.2015	31.03.2016	31.03.2015
	Audited	Audited	Audited	Audited
A. EQUITY AND LIABILITIES				
1. Shareholder's funds				
(a) Share Capital	771.02	771.02	771.02	771.02
(b) Reserves and Surplus	66391.43	55538.56	63919.28	53923.10
Sub.total-Shareholder's funds	67162.45	56309.58	64690.30	54694.12
2. Minority Interest	0.00	0.00	1476.37	1438.68
3. Non-Current Liabilities				
(a) Long-term borrowings	0.00	1622.82	9753.82	10232.90
(b) Deferred tax liabilities (net)	4846.61	3931.21	3586.99	3776.92
(c) Other Long term liabilities	0.00	0.00	350.93	230.51
(d) Long-term provisions	390.00	388.68	1354.09	1174.94
Sub.total-Non-current liabilities	5236.61	5942.72	15045.84	15415.28
4. Current Liabilities				
(a) Short-term borrowings	6959.37	5084.21	8698.43	5846.62
(b) Trade payables	5895.81	6557.89	10144.04	7550.36
(c) Other current liabilities	3602.43	3827.83	6065.85	4932.09
(d) Short-term provisions	46.15	542.84	73.04	577.40
Sub.total-Current liabilities	16503.76	16012.77	24981.36	18906.47
TOTAL-EQUITY AND LIABILITIES	88902.82	78265.07	106193.86	90454.55
B. ASSETS				
1. Non-current Assets				
(a) Goodwill on Consolidation	0.00	0.00	2312.23	1765.76
(b) Fixed assets (Net Block)				
(i) Tangible /Intangible assets	35523.00	28001.31	55727.70	29839.80
(ii) Capital work-in-progress	8937.85	8771.30	9472.90	22162.20
Sub.total-Fixed assets	44460.85	36772.60	67512.83	53767.76
(c) Non current investments	10078.53	7424.44	24.25	18.99
(d) Long-term loans and advances	5920.79	5568.64	4340.71	3890.40
(e) Other non-current assets	0.00	0.00	0.60	16.21
Sub.total-Non-current assets	60460.17	49765.69	71878.39	57693.36
2. Current Assets				
(a) Current investments	5272.55	6535.40	5272.55	6535.40
(b) Inventories	12465.87	12087.59	16250.65	13078.29
(c) Trade receivables	7127.42	7012.04	8459.06	8137.08
(d) Cash and cash equivalents	583.91	249.06	1588.23	1841.72
(e) Short-term loans and advances	1895.20	2333.24	2390.11	2772.10
(f) Other current assets	1097.69	282.05	354.88	396.59
Sub.total-Current assets	28442.65	28499.38	34315.47	32761.19
TOTAL-ASSETS	88902.82	78265.07	106193.86	90454.55

By the order of the Board of Directors
for SHILPA MEDICARE LIMITEDPlace:Hyderabad
Date:30/05/2016

Chairman


**Auditor's Report on Quarterly Financial Results and Year to date Results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To
Board of Directors of
Shilpa Medicare Limited

1. We have audited the quarterly financial results of Shilpa Medicare Limited ('the Company') for the quarter ended March 31, 2016 and the financial results for the year ended March 31, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2016 and the published year to date figures upto December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subject to limited review. These quarterly financial results as well as the year to date financial results have been prepared on the basis of unaudited financial results for the nine-month period ended December 31, 2015, the audited annual financial statements as at and for the year ended March 31, 2016 and the relevant requirement of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the financial statements for the nine-month period ended December 31, 2015, which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting specified under the Section 133 of the Companies Act 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2016; and the relevant requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion.
3. **Matter of Emphasis**
Without qualifying our report on the audited financial results, we state that the Company has filed a lawsuit for recovering its amount of Rs.344.83 Lakhs which is paid as capital advance to its vendor for supply of Capital Asset, along with punitive damages. The hearing of the case is in progress. The ultimate outcome of the matter cannot presently be determined, and hence no provision for the outstanding balance receivable from the party has been made in the financial statements. Our Report is not qualified on this matter.
4. In our opinion and to the best of our information and according to the explanations given to us and read with paragraph 3 above, these quarterly financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015; and
 - ii. give a true and fair view of the net profit for the quarter ended March 31, 2016 and for the year ended March 31, 2016.



5. Further, read with paragraph 1 above, we also report that the figures for the quarter ended March 31, 2016 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in Paragraph 1 above, as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

For Bohara Bhandari Bung & Associates LLP
Chartered Accountants
ICAI Firm Regn No. 008127S/S200013

amp gjs

CA.Pankajkumar Bohara
Partner
Membership No: 215471

Place / Camp: Hyderabad
Date: 30.05.2016



**Auditor's Report on Quarterly Consolidated Financial Results and Consolidated Year to date
Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015**

To
Board of Directors of
Shilpa Medicare Limited

1. We have audited quarterly consolidated financial results of Shilpa Medicare Limited ('the Company'), its Subsidiaries and Joint venture ("Collectively known as Group") for the quarter ended March 31, 2016 and the Consolidated financial results for the year ended March 31, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The Quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2016 and the published year to date figures upto December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The Consolidated financial results for the quarter ended March 31, 2016 have been prepared on the basis of the consolidated financial results for the nine-month period ended December 31, 2015, the audited annual consolidated financial statements as at and for the year ended March 31, 2016, and the relevant requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Consolidated financial results based on our review of the consolidated financial results for the nine-month period ended December 31, 2015 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, our audit of the annual financial statements as at and for the year ended March 31, 2016; and the relevant requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion.
3. We did not audit revenues (including other Income) of Rs.2,4441.81 Lakhs and Rs.4,979.26 Lakhs for the quarter and year ended March 31, 2016, respectively and assets of Rs.25,615.68 Lakhs as at March 31, 2016, relating to 03 subsidiaries and 01 Joint Venture (JV) included in the accompanying consolidated financial results for the quarter and year ended March 31, 2016.

These unaudited financial statements and other financial information of the above subsidiaries and JV have been prepared by the management and furnished to us, and our opinion is based solely on these unaudited financial statements.

4. We did not audit revenues (including other income) of Rs78.50 Lakhs and Rs.245.55 Lakhs for the quarter and year ended March 31, 2016, respectively and assets of Rs.5,562.86 Lakhs as at March 31, 2016 relating to 02 subsidiaries included in the accompanying consolidated financial results for the quarter and year ended March 31, 2016.

The financial statements of the above subsidiaries have, been audited by other auditors whose reports have been furnished to us, and our opinion on these consolidated quarterly financial results and the consolidated year to date results is based solely on the report of such other auditors.



5. We draw attention to note no.10 in the attached statement of consolidated financial results regarding the decision of one of its subsidiary Company's management to charge off the Product Registration fees amounting to Rs.118.78 Lakhs (PY Nil) to Profit & Loss Account which is against the Holding company's policy of capitalizing such charges as Intangible Assets. This has resulted in decrease in the consolidated net profit of the Company by said amount. Our opinion is not qualified in respect of this matter.
6. **Matter of Emphasis**
Without qualifying our report on the audited financial results, we state that the Company has filed a lawsuit for recovering its amount of Rs.344.83 Lakhs which is paid as capital advance to its vendor for supply of Capital Asset, along with punitive damages. The hearing of the case is in progress. The ultimate outcome of the matter cannot presently be determined, and hence no provision for the outstanding balance receivable from the party has been made in the financial statements. Our Report is not qualified on this matter.
7. In our opinion and on consideration of reports of other auditors on separate financial statements which have been audited by them and to the best of our information and according to the explanations given to us, together read with note no.05 & 06 above these quarterly consolidated financial results as well as consolidated year to date results:
- includes the quarterly financial results and year to date results of the following entities:
 - Shilpa Medicare Limited (Holding Company)
 - Koanaa Healthcare Limited (Wholly owned subsidiary Company)
 - Zatortia Holdings Limited (Wholly Owned Subsidiary Company)
 - Raichem Medicare Private Limited (Subsidiary Company)
 - Nu Therapeutics Private Limited (Subsidiary Company)
 - INM Technologies Private Limited (Subsidiary Company)
 - Makindus, Inc (Subsidiary Company)
 - Loba Feinchemie,Gmbh (Step down Subsidiary Company)
 - MAIA Pharmaceuticals, Inc (Joint Venture Company)
 - Reva Medicare Private Limited (Joint Venture Company)
 - are presented in accordance with the requirements Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, in this regard; and
 - give a true and fair view of the consolidated net profit for the quarter ended March 31, 2016 as well as the consolidated year to date results for the year ended March 31, 2016.

For Bohara Bhandari Bung & Associates LLP
Chartered Accountants
ICAI Firm Regn No. 008127S/S200013

CA.Pankajkumar Bohara
Partner
Membership No. 215471

Place / Camp: Hyderabad
Date: 30.05.2016





Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006, 235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

CIN No. L85110KA1987PLC008739

SML/22/2016-17

Dated 30th May, 2016

To
Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

To
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Declaration under Regulation 33 (3) (d) of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015
REF: Scrip Symbol: SHILPAMED**

We hereby declare that the Audit Report Submitted alongwith the Annual Audited Financial Results for the quarter and year ended 31st March, 2016, is unmodified i.e the Audit Report does not contain any modified opinion.

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI(Listing Obligations and Disclosure requirements) Regulations, 2015 and amendments thereon.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,
For **SHILPA MEDICARE LIMITED**


OMPRAKASH INNANI
CHAIRMAN
DIN No:01301385

